Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07358195 · ClinicalTrials.gov registry record · Early Phase 1
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT07358195: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07358195 is a Early Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07358195, a Early Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.
Interventions
- DRUG Venetoclax
- PROCEDURE Hematopoietic Cell Transplantation
- PROCEDURE Kidney Transplant
- PROCEDURE Hematopoietic Cell Transplantation Conditioning Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07358195
The ClinicalTrials.gov registry entry for NCT07358195 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT07358195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07358195 about?
NCT07358195 is a clinical study titled "Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation". The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetocl...
What is the current status of trial NCT07358195?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2026-07. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07358195?
The interventions under investigation include: Venetoclax (DRUG), Hematopoietic Cell Transplantation (PROCEDURE), Kidney Transplant (PROCEDURE), Hematopoietic Cell Transplantation Conditioning Regimen (PROCEDURE).
Who is sponsoring clinical trial NCT07358195?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.